ArticleEmerging microbes & infections2020
PCR ribotypes of
Article in Emerging microbes & infections, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 24 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
24 citing papers in PubMed, 29 citations in OpenAlex.
- Efficacy, Safety, Pharmacokinetics, and Microbiome Changes of Ibezapolstat in Adults with Clostridioides difficile Infection: A Phase 2a Multicenter Clinical Trial.Clinical infectious diseases : an official publication of the Infectious Diseases Society of America · 2022Trial
- Ecological and dietary strategies to constrain Clostridioides difficile.Cell host & microbe · 2026Review
- Variety ofGerms · 2026Article
- Bridging the gap in AMR research: validation of a standardizedFrontiers in pharmacology · 2026Article
- Isolation ofAnimals : an open access journal from MDPI · 2025Article
- EmergingmSystems · 2025Article
- Reduced Vancomycin Susceptibility inOpen forum infectious diseases · 2024Article
- EmergingbioRxiv : the preprint server for biology · 2024Article
- Genomic study of EuropeanMicrobial genomics · 2024Article
- Antibacterial activity of ibezapolstat against antimicrobial-resistant clinical strains ofAntimicrobial agents and chemotherapy · 2024Article
- The Strain and the Clinical Outcome ofOpen forum infectious diseases · 2024Article
- Assessing the Feasibility of Employing a Combination of a Bacteriophage-Derived Endolysin and Spore Germinants to Treat RelapsingMicroorganisms · 2023Article
- Surveillance of Clostridioides difficile Antimicrobial Resistance in the United States.Clinical infectious diseases : an official publication of the Infectious Diseases Society of America · 2023Article
- Prevalence of diagnostically-discrepantFrontiers in medicine · 2023Article
- Sentinel surveillance and epidemiology ofEuro surveillance : bulletin Europeen sur les maladies transmissibles = European communicable disease bulletin · 2022Article
- Make It LessGenes · 2022Review
- Isolation, molecular typing and antimicrobial resistance ofFrontiers in veterinary science · 2022Article
- Article
- Article
- Temporal Variations in Patterns ofAntibiotics (Basel, Switzerland) · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors at 5 institutions in 1 country.
Funding
Abstract
PubMed holds no abstract for this paper.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.